Former Chair of City of Hope Department of Pediatrics Joins NDA Partners as Expert Consultant

0

CEO of NDA Partners, Eric Fishtoday announced that Joseph Rosenthal, MD, board-certified pediatric hematologist/oncologist and expert in the field of hematopoietic stem cell transplantation, has joined the company as an expert consultant. Dr. Rosenthal has been associated with City of Hope for over 20 years, where he led the Pediatric Hematology/Oncology Program and served as Endowed Chair of the Department of Pediatrics.

WASHINGTON, May 4, 2022 /PRNewswire-PRWeb/ — Managing Director of NDA Partners, Eric Fishtoday announced that Joseph RosenthalMD, a board-certified pediatric hematologist/oncologist and expert in the field of hematopoietic stem cell transplantation, has joined the company as an expert consultant. Dr. Rosenthal has been associated with City of Hope for over 20 years, where he led the Pediatric Hematology/Oncology Program and served as Endowed Chair of the Department of Pediatrics. Previously, he was a member of the Leadership Team for the Pediatric Hematology/Oncology/Bone Marrow Transplant Program at Children’s Hospital of Orange County, California. He was also a faculty member of Pediatric Oncology at Rambam Medical Center in Haifa, Israel and Faculty of Pediatric Hematology and Oncology at Soroka Medical Center in Beer Sheba, Israel.

Dr. Rosenthal’s research focuses on developing modalities that offer reduced organ toxicity, such as the incorporation of total marrow and lymphoid irradiation (TMLI) as an alternative to total body irradiation (TBI) and the study of cord blood units and haploidentical transplants to expand the donor pool for patients who do not have matched related or unrelated donors. He is actively involved in the development of HCT as a treatment for sickle cell disease and in the development of gene therapy modalities for genetic disorders. He is an investigator in clinical trials sponsored by the Pediatric Bone Marrow Transplant (BMT) Consortium and the BMT Clinical Trial Network. According to dr. Ellen FeigalHead of NDA Partners’ Biologics Practice, “Dr. Rosenthal’s extensive clinical and research experience in pediatric hematopoietic stem cell transplantation will be invaluable to our clients who are developing therapies for pediatric patients.”

Dr. Rosenthal received his medical degree from the Sackler School of Medicine in Tel Aviv University, Tel Aviv, IsraelMasters in Health Care Management from Harvard School of Public Healthand a bachelor’s degree Hebrew University, Jerusalem, Israel. He completed his residency at Soroka Medical Center, Beer Sheba, Israel and Pediatric Hematology/Oncology Fellowship at University of Colorado School of Medicine Denver, Colorado and Pediatric Cancer Research and Bone Marrow Transplantation at the Children’s Hospital of Orange County, Orange, California.

About NDA Partners
NDA Partners, a ProPharma Group is a life sciences management consulting and contract development organization focused on providing product development and regulatory services to the pharmaceutical, biotechnology and medical device industries worldwide. NDA Partners’ highly experienced expert consultants include three former FDA Center Directors; former CEO and Scientific Director of the United States Pharmacopeial Convention (USP); an international team of more than 100 former senior executives from the pharmaceutical industry and regulatory agencies; and an extensive roster of highly skilled experts in specialist areas including non-clinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions and management of development programs. Services include product development and regulatory strategy, product development program design and management, expert consulting, functional teams, project-based solutions, and clinical trial design and management. .

Contact
Eric FishGeneral director
Office: 540-738-2550
FishEric@ndapartners.com

Media Contact

Eric FishNDA Partners, 540-738-2550, FishEric@ndapartners.com

SOURCE NDA Partners

Share.

Comments are closed.